1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Mycenax Biotech Inc.

Mycenax Biotech Inc.

TTPEX:4726
22.45
TWD
-0.45
(-1.97%)
-1.84EPS
5.30BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.68
1.02
1.22
1.83
2.9
1.92
3.11
5.2
5.21
4.43
3.18
3.32
3.57
3.94
Basic EPS, GAAP
-0.94
-0.79
-1.01
-1.45
-1.71
-2.5
-1.74
0.24
-0.61
-2.74
-3.32
-2.27
-2.17
-1.84
Free Cash Flow per Basic Share
-1.09
-2.04
-1.17
-3.25
-1.25
-2.74
-2.54
-0.69
-8.48
-4.77
-2.09
-2.53
-0.61
-0.11
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
15.47
14.76
13.03
11.75
10.41
8.25
10.02
9.45
12.43
15.13
11.9
9.77
7.72
6.8
Tangible Book Value per Share
15.44
14.74
13.03
11.73
10.39
8.13
9.34
8.98
12.06
14.88
11.69
9.6
7.52
6.59
Basic Weighted Avg Shares
94
111
110
110
110
110
126
128
148
165
206
206
207
207
Sales/Revenue/Turnover
64
113
135
201
319
211
391
665
774
732
653
684
740
816
Operating Margin (%)
-169.8
-117.47
-104.61
-108.87
-38.12
-151.76
-58.64
6.95
-11.95
-56.51
-92.43
-67.48
-54.76
-43.46
Depreciation Expense
18
20
35
42
63
80
123
137
168
283
315
303
284
309
Net Income, GAAP
-89
-87
-111
-158
-188
-274
-218
31
-90
-454
-683
-467
-449
-382
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-138.59
-77.05
-82.23
-79
-59.12
-129.8
-55.82
4.65
-11.61
-61.95
-104.63
-68.3
-60.61
-46.81
Working Capital
1,544
1,414
1,183
866
638
285
263
152
357
1,289
345
75
-330
-562
LT Debt
- -
- -
- -
- -
38
29
33
72
650
713
570
683
556
439
Total Equity
1,706
1,637
1,454
1,316
1,144
907
1,102
1,212
1,907
3,106
2,447
2,023
1,599
1,408
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-9.4
-5.21
-7.17
-11.44
-15.31
-26.76
-21.72
2.68
-5.76
-18.1
-24.59
-20.9
-24.77
-24.06

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
516
686
685
LT Borrowings
434
385
335
LT Finance Leases
122
113
104
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
207
207
207
Market Capitalization
6,549
6,394
5,300

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
776
848
870
Cash, Cash Equivalents & STI
226
218
265
Accounts Receivable, Net
106
127
44
Inventories
133
172
176
Total Current Liabilities
1,106
1,359
1,432
Payables & Accruals
- -
- -
- -
ST Debt
516
686
685
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.89%
12.15%
-20.98%
Free Cash Flow
136.05%
238.51%
-75.81%
Net Income, GAAP
0.22%
5.89%
-3.96%
Sales/Revenue/Turnover
24.21%
2.62%
8.23%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
80
201
209
194
684
2025
122
203
131
285
740
2026
197
203
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.66
-0.49
-0.71
-0.4
-2.27
2025
-0.62
-0.66
-0.63
-0.25
-2.17
2026
-0.56
-0.4
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pei Chun Chen
Full Time Employees
387
Sector
Health technology
Industry
Biotechnology
Address
No. 66, Shengyi 2nd Road Miaoli Taiwan 302041
IPO Date
Oct 30, 2008
Website
mycenax.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Mycenax Biotech Inc. (TWO:4726) is a contract development and manufacturing organization (CDMO) specializing in biologics and biosimilars, providing end-to-end biopharmaceutical services from cell line development and process development to PIC/S GMP-compliant manufacturing of drug substances and drug products. Founded in 2001 and headquartered in Zhubei, Taiwan, the company operates two GMP facilities approved by regulators including the European Medicines Agency (EMA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Korea's Ministry of Food and Drug Safety (MFDS), and Health Canada; it serves clients in Taiwan, Japan, Korea, Singapore, other Asia-Pacific regions, Europe, and the United States. Core offerings encompass mammalian manufacturing of monoclonal antibodies, bispecific/multispecific antibodies, and recombinant proteins; microbial manufacturing of plasmid DNA, recombinant proteins, and enzymes; antibody-drug conjugates including conjugation technology and linkers; cell and gene therapy modalities such as stem cell therapy, immune cell therapy, CAR genetic engineering, and exosomes; plus analytics services like analytical method development/validation and testing. Mycenax supports developability assessment, program evaluation, drug characterization, and tech transfer, leveraging integrated platforms for efficient, cost-effective solutions in traditional and emerging therapies. The company develops and manufactures products including fc-fusion proteins, peptides, protein conjugates, antibody-cell conjugates, antigen-binding fragments (Fab), single-chain variable fragments (ScFv), and DNA vaccines from mammalian and microbial cell lines.